This study investigates Tumor Hyperinsulinism. It looks at the effects of an investigational medication given alongside standard treatments.
The study evaluates the safety, effectiveness, and tolerability of the investigational medication for managing symptoms related to Tumor Hyperinsulinism.
- Who can participate: Adults aged 18 and over with a clinical diagnosis of neuroendocrine tumor causing hyperinsulinism may participate. Participants must have failed standard therapies and require specific medical support for hypoglycemia.
- Study details: Participants will receive weekly doses of the investigational medication alongside their usual treatment for 8 weeks.